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Summary
We describe de novo generation of IL-17-producing T
cells from naive CD4 T cells, induced in cocultures of
naive CD4 T cells and naturally occurring CD4+ CD25+
T cells (Treg) in the presence of TLR3, TLR4, or TLR9
stimuli. Treg can be substituted by TGFb1, which, to-
gether with the proinflammatory cytokine IL-6, sup-
ports the differentiation of IL-17-producing T cells,
aprocess that is amplifiedby IL-1bandTNFa.Wecould
not detect a role for IL-23 in the differentiation of IL-17-
producingTcellsbut confirmed its importance for their
survival and expansion. Transcription factors GATA-3
and T-bet, as well as its target Hlx, are absent in IL-17-
producingTcells, and theydonot express thenegative
regulator for TGFb signaling, Smad7. Our data indicate
that, in the presence of IL-6, TGFb1 subverts Th1 and
Th2 differentiation for the generation of IL-17-produc-
ing T cells.
Introduction
CD4+ T cells can be divided into different subsets with
distinct differentiation profiles and functional character-
istics. The best-characterized subsets are Th1, Th2, and
Treg, whose development is specified by the transcrip-
tion factors Tbet, GATA-3, and Foxp3, respectively (Fon-
tenot et al., 2005; Szabo et al., 2000; Zheng and Flavell,
1997). A unique subset characterized by production of
IL-17 and crucially involved in the pathogenesis of cer-
tain autoimmune diseases such as rheumatoid arthritis
and EAE as well as allergen-specific responses was re-
cently identified (Cua et al., 2003; Kolls and Linden,
2004; Langrish et al., 2005; Nakae et al., 2002). IL-17 pro-
motes granulopoiesis and neutrophil accumulation,
and, while it plays an active role in inflammatory dis-
eases, also has been shown to protect mucosal barrier
functions due to stimulation of tight junction formation
and mucin secretion (Chen et al., 2003b; Kinugasa
et al., 2000). Thus, neutralization of IL-17 enhances dex-
*Correspondence: bstocki@nimr.mrc.ac.uktran sulfate sodium (DSS)-induced inflammatory bowel
disease (Ogawa et al., 2004).
It has so far been unclear how de novo differentiation
of IL-17-producing T cells is stimulated. Although DC-
derived IL-23 was shown to increase IL-17 secretion
from activated CD4+ T cells (Aggarwal et al., 2003;
Langrish et al., 2005), IL-23 is not sufficient to induce dif-
ferentiation of IL-17-producing cells from naive CD4+ T
cells in vitro, suggesting the involvement of additional
or other factors in the de novo development of this T
cell subset. The rationale underlying the existence of
multiple subsets of CD4+ T cells is their crucial role in or-
chestration and control of immune responses. Cytokine-
mediated crossregulation of each other’s responses is
an important principle of immune regulation (O’Garra
et al., 2004), involving IL-4-mediated downregulation of
IL-12Rb2 (Szabo et al., 1997) or IFN-g mediated inhibi-
tion of Th2 development (Fitch et al., 1993). In addition,
interference strategies involving suppressive cytokines
such as TGFb1 (Letterio and Roberts, 1998) or IL-10
(Moore et al., 2001) play an important role in the control
of immune responses. These immunoregulatory func-
tions are strongly influenced by interactions with den-
dritic cells that act as go betweens for the innate and
adaptive immune system through integration of patho-
gen-derived signals and release of immune-modulating
mediators (Reis e Sousa, 2004). The naturally occurring
CD4+ CD25+ T cell subset (Treg) has been suggested to
be dedicated to the control of immune pathology and
autoimmunity, substantiated by the finding that absence
of the Foxp3 transcription factor that controls the gener-
ation of this subset results in a fatal autoimmune disor-
der (Fontenot and Rudensky, 2005; Sakaguchi, 2005).
Treg suppress the expansion of potentially pathogenic
T cells in vivo (Almeida et al., 2002; Annacker et al.,
2000; Maloy and Powrie, 2001) and inhibit the prolifera-
tion and IL-2 transcription of naive CD4+ T cells in vitro
(Thornton and Shevach, 1998). Interestingly, however,
it appears that Treg do not suppress T cell proliferation
in vitro in the presence of an inflammatory stimulus such
as LPS. The blockade of suppression under these con-
ditions was attributed to the secretion of IL-6 and other
unidentified cytokine(s) by LPS-stimulated dendritic
cells acting on the responder CD4+ T cells (Pasare and
Medzhitov, 2003). In this paper, we show that, despite
restoration of proliferative function in CD4 T cells cul-
tured with Treg in the presence of LPS, their IL-2 and
especially their IFN-g responses are still profoundly sup-
pressed. However, the presence of Tregs in a proinflam-
matory cytokine milieu resulted in differentiation of naive
CD4+ T cells to IL-17 production. We provide evidence
that the component involved in differentiation of naive
CD4 T cells to IL-17 producers is TGFb1, which, together
with DC-derived IL-6, is essential for de novo differenti-
ation of IL-17-producing T cells from naive CD4 T cells
in vitro, a process that is amplified by IL-1b and TNFa.
IL-17-producing T cells are distinct from Th1 T cells,
as shown by absence of IFN-g transcription as well as
absence of the transcription factor T-bet and its target
Hlx. Our data indicate that a critical balance of pro- and
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180Figure 1. LPS Stimulation Overcomes Treg-
Mediated Inhibition of Proliferation but Not
IL-2 and IFN-g and Results in IL-17 Produc-
tion
FACS-sorted naive CD4+ T cells and BMDC
were stimulated with anti-CD3 alone or in
a 1:1 mixture with FACS-sorted Treg in the
absence (white bars) or presence (black
bars) of LPS. (A) Proliferation was assessed
after 48 hr by 3H-thymidine incorporation;
(B) IL-2 protein in culture supernatants as-
sessed by CTLL-2-assay. (C and D) mRNA
for IL-2 assessed at 1–2 hr intervals, of
BMDC and naive CD4+ T cells alone (trian-
gles) or mixed with Tregs (circles), in the ab-
sence (C) or presence (D) of LPS. Values are
plotted as fold increase over mRNA levels in
DC at time point 0. (E), (F), (G), and (H) show
intracellular staining for IFNg and IL-17 of
CD4+ T cells (gated on naive T cell input), cul-
tured for 4 days as described above. Shown
are naive cells alone (E), mixed with Treg (F),
naive alone in presence of LPS (G), and mixed
with Treg (H). Error bars represent SD values.antiinflammatory cytokines is conducive to differentia-
tion of IL-17-producing T cells, thereby potentially
tipping the balance toward more severe inflammatory
reactions that might aggravate immune pathology.
Results
Coculture of Naive CD4 T Cells with Treg
in the Presence of LPS Induces IL-17 Production
Coculture of naive CD4 T cells and Treg at a 1:1 ratio in
the presence of DC and LPS abrogates the suppressive
function of Treg on T cell proliferation, as previously
shown (Pasare and Medzhitov [2003] and Figure 1A).However, the IL-2 response remained suppressed, as
indicated by the reduced amounts of IL-2 protein in
the supernatant whether or not LPS was present in the
cultures (Figure 1B). Since it is difficult to quantitate
IL-2 protein levels in these cocultures due to the sub-
stantial consumption of IL-2 by Treg (Barthlott et al.,
2005; de la Rosa et al., 2004), we assessed levels of
mRNA for IL-2. While, in cocultures of naive CD4 T cells
and Treg in the presence of DC and LPS, mRNA levels
for IL-2 were partially restored compared with cocul-
tures without LPS, the major peak of IL-2 message
around 6 hr after activation remained absent (Figures
1C and 1D). Furthermore, the suppression of IFN-g-
producing cells, which is evident in the presence of
Differentiation of IL-17-Producing T Cells
181Figure 2. Treg Provide TGFb for Differentiation of IL-17-Producing CD4+ T Cells
FACS-sorted naive CD4+ T cells were mixed 1:1 with FACS-orted Treg and cultured for 4 ays with BMDC, anti-CD3, nd LPS and (A) isotype control
antibody, (B) anti-TGFb, or (C) anti-IL-10. Naie CD4+ T cells cultured under identical conditions as above, but in the absence of Treg, are shown in
the absence (D) or presence (E) of TGFb. Dot plots show intracellular staining for IFNg and IL-17 of CD4+ T cells, gated on the naie CD4+ T cell
input. (F) Naive CD4+ T cells cultured as above, in presence of indicated concentrations of TGFb1. Percentages of IL-17-negative (closed bars) or
IFNg-positive (open bars) T cells are shown.Treg (Figure 1E versus Figure 1F) was still enforced in
the presence of LPS (Figure 1, GvsH). However, instead
of IFN-g, a substantial proportion of CD4 T cells cocul-
tured with Treg in the presence of LPS secreted IL-17
(Figure 1H versus Figure 1G), and this effect titrated
with the number of Treg present in the culture (see Fig-
ure S1 in the Supplemental Data available with this arti-
cle online).
The Component Involved in Differentiation
of IL-17 Producers Is TGFb1
Tregs are known to be a potent source of TGFb1, an im-
munosuppressive cytokine produced by multiple cell
types (Maloy and Powrie, 2001). IL-10 is another sup-
pressive cytokine implicated in the action of Treg, but
its delayed induction in T cells in vitro (Barthlott et al.,
2005) makes it a less likely candidate in the differentia-
tion of IL-17 producers. In order to test the involvement
of TGFb1 or IL-10 in this process, neutralizing antibodies
specific for either TGFb or IL-10 were added to cocul-
tures of naive CD4+ T cells, Treg, and DC in the presence
of LPS. As shown in Figure 2B, the addition of anti-TGFb
suppressed the generation of IL-17-producing T cells,
whereas anti-IL-10 only caused a slight reduction in
the proportion of IL-17-producing T cells (Figure 2C).
Furthermore, addition of as little as 25 pg/ml of TGFb1
to cultures of naive T cells with DC and LPS without
any Treg was sufficient to deviate differentiation from
Th1 T cells (Figure 2D) to IL-17-producing T cells (Fig-
ures 2E and 2F).DCs Stimulated by Different TLR Ligands
in a MyD88-Dependent Fashion Are Crucial
for CD4 Differentiation to IL-17 Production
Given that generation of IL-17-producing CD4 T cells de-
pended on the presence of LPS, the involvement of
TLR4 triggering of DC seemed essential for this path-
way. In order to test whether other TLR ligands could
substitute for LPS, we added either CpG or polyI:C, trig-
gering TLR9 or TLR3, respectively, to cultures contain-
ing naive CD4 T cells, Treg, and DC. As shown in Figures
3A and 3B, ligands for TLR3 and -9 were also able to in-
duce differentiation of IL-17-producing T cells. The ab-
sence of IL-17-producing T cells in cultures containing
DC from MyD882/2 mice (Figure 3D) compared with
wild-type DC in the presence of LPS (Figure 3C) sug-
gests the involvement of inflammatory cytokines rather
than mere upregulation of costimulatory molecules on
DC, a process that is MyD88 independent (Kaisho
et al., 2001). In order to determine whether cell-cell con-
tact between DC and T cells was essential for differenti-
ation to IL-17 or whether soluble mediators secreted by
DC were sufficient, DC-free cultures were set up, and
activation of naive CD4 T cells was achieved by addition
of beads coated with anti-CD3 and anti-CD28. Figures
3E and 3F show that addition of LPS to naive CD4 T cells
on their own or in the presence of Treg does not suffice
to induce either IFN-g or IL-17 differentiation, ruling out a
direct effect of LPS on T cells and illustrating the impor-
tance of DC for T cell differentiation processes. The ad-
dition of conditioned medium (CM) from LPS-stimulated
Immunity
182Figure 3. Differentiation of IL-17-Producing CD4+ T Cells Requires
a DC Factor or Factors that Are Soluble, MyD88 Dependent, and
Induced by TLR Ligation
Panels show intracellular staining for IFNg and IL-17 of CD4+ T cells,
gated on the naive CD4+ T cell input after 4 days of culture. FACS-
sorted naive CD4+ T cells were mixed 1:1 with FACS-sorted Treg
and cultured with BMDC, anti-CD3 and either PolyI:C (A) or CpG
(B). Purified naive CD4+ T cells were cultured with either C57BL/6
BMDC (C) or C57BL6 MyD882/2 BMDC (D), and anti-CD3, LPS,
and TGFb. Sorted naive CD4+ T cells were cultured with anti-CD3
and anti-CD28 coated beads and LPS in the absence (E) or presence
of equal numbers of sorted Treg (F). CM was obtained from BMDC
cultured for 12–14 hr in the presence of LPS. Sorted naive CD4+ T
cells were cultured in this medium with anti-CD3- and anti-CD28-
coated beads in the absence (G) or presence of TGFb (H).DC on its own caused differentiation of IFN-g producers
(Figure 3G). However, in the presence of TGFb1, CM
from LPS stimulated DC-induced IL-17-producing
CD4+ T cells and suppression of IFN-g-producing Th1
cells (Figure 3H). Thus, soluble mediator(s) from DC to-
gether with TGFb1 are important for differentiation of
IL-17-producing T cells.
Identification of DC-Derived Cytokines Involved
in Differentiation of IL-17 Producers
Previous reports suggested that IL-23 is a crucial cyto-
kine in the development of IL-17-producing CD4+ T cells,
although as yet no studies have shown that IL-23 will di-
rect the differentiation of naive CD4 T cells into IL-17-
producing T cells (Langrish et al., 2005; Murphy et al.,
2003; Vanden Eijnden et al., 2005). We show here that
the addition of anti-p40 antibody, which blocks both
IL-12 and IL-23, to cultures of naive CD4+ T cells with
TGFb1 and CM from LPS-stimulated DC does not
suppress IL-17 production (Figure 4C). IL-6 is a likely
candidate for the generation of IL-17-producing T cells,
because we first detected their development in the ex-
perimental system described by Pasare et al. in which
IL-6 was described to overcome the proliferative defect
of naive CD4 T cells when cocultured with Treg (Pasare
and Medzhitov, 2003). Furthermore, IL-6 and IL-23p19
are closely related members of the subfamily of helical
cytokines, exhibiting a wide range of often overlapping
biological functions (Oppmann et al., 2000). Indeed, ad-
dition of a neutralizing antibody specific for IL-6 to cul-
tures of naive CD4+ T cells and DC-conditioned medium
abolished the generation of IL-17 producers (Figure 4D),
thus supporting the assumption of its involvement. In a
DC free culture system with anti-CD3- and anti-CD28-
coated beads, addition of IL-6 together with TGFb1 to
naive CD4 T cells stimulated by antibody-coated beads
induced a dose-dependent increase in IL-17 differentia-
tion (Figure 4E, panels). The differentiation of IL-17-pro-
ducing T cells was further augmented by the presence of
two additional DC-derived proinflammatory cytokines,
TNFa and IL-1b (Figure 4F).
Addition of IL-23 induced a low degree of Th1 devel-
opment but no IL-17, whether alone or in combination
with TGFb1 (Figures 4G and 4H), thus making it unlikely
that this cytokine is responsible for de novo generation
of IL-17-producing T cells. Various blocking antibodies
and additional cytokine combinations were tested
(shown in Figure S2), further emphasizing the obligatory
role IL-6 and TGFb1 are playing in the differentiation of
IL-17-producing T cells and illustrating the accessory
function of IL-1b and TNF-a.
Distinction of Th1 and IL-17-Producing T Cells
and an Active Role for TGFb1
In order to study the differentiation of IL-17-producing
CD4+ T cells and their relation to Th1 cells, we made
use of IFN-g gene knockin bicistronic reporter mice
(Yeti) expressing a yellow fluorescent protein (eYFP)
(Stetson et al., 2003). Modification of the IFN-g locus al-
lowing access to transcription factors correlates with
the presence of mRNA and is reported by YFP staining.
While Yeti mice faithfully report the presence of cytokine
mRNA, translation of the downstream fluorescent re-
porter is less stringently regulated, and cells that have
Differentiation of IL-17-Producing T Cells
183Figure 4. Differentiation of IL-17-Producing CD4+ T Cells Requires Combinations of DC-Derived Proinflammatory Cytokines
Dot plots show intracellular staining for IFNg and IL-17 of sorted naive CD4+ T cells after 4 days of culture with anti-CD3- and anti-CD28-coated
beads. (Top row) CD4+ T cells cultured in CM from DC stimulated with LPS for 12–14 hr (A), CM supplemented with TGFb (B), or supplemented
with TGFb and anti-IL-12/IL-23 (C), or TGFb and anti-IL-6 (D). (Second row) CD4+ T cells cultured with anti-CD3- and anti-CD28-coated beads and
TGFb, and indicated concentrations of IL-6 (E), or IL-6, IL-1b, and TNFa (F). (Third row) CD4+ T cells cultured with anti-CD3- and anti-CD28-coated
beads with IL-23 (G), or IL-23 in combination with TGFb (H).once upregulated IFN-g remain YFP positive. Therefore,
it is possible to ascertain whether an IL-17-producing T
cell has ever opened the IFN-g locus during differentia-
tion and thus would allow us to see whether Th1 and IL-
17-producing T cells are related, as has previously been
suggested (Bettelli et al., 2004). In vitro stimulation of
YFP-negative sorted naive CD4+ T cells from Yeti mice
with DC in the presence of LPS induced YFP-positive
(IFN-g producing) T cells (Figure 5A), whereas the addi-
tion of TGFb induced IL-17 production but no YFP-pos-
itive T cells (Figure 5B), indicating that differentiation to
IL-17 progresses without opening of the IFN-g locus.
In fact, the addition of neutralizing antibodies to IL-12/
23, IFNg, and IL-4 without addition of TGFb1 was suffi-
cient to induce the differentiation of IL-17-producing T
cells in the presence of LPS-stimulated DC (Figure 5C).
This result is in line with a role for TGFb1 in preventingTh1 and Th2 differentiation in the presence of IL-6,
thus allowing the diversion to differentiation of IL-17-
producing T cells. However, in a DC-free system, addi-
tion of the Th1/Th2 blocking antibody cocktail could
not substitute for TGFb1 and thus did not result in IL-
17-producing T cells (Figure 5D). The apparent paradox
is resolved by the finding that addition of anti-TGFb1 to
cultures containing DC prevented the appearance of IL-
17-producing T cells despite the presence of neutraliz-
ing antibodies to IL-12/23, IFNg, and IL-4 (Figure 5F).
Thus, LPS-stimulated DC produce TGFb1 themselves,
albeit in amounts that cannot support IL-17 differentia-
tion without further blockade of cytokines that promote
differentiation of the other T cell subsets. We observed
that addition of IL-12, IL-18, or IL-4 to primary
cultures containing IL-17-promoting cytokines resulted
in dose = -dependent reduction of IL-17-producing
Immunity
184Figure 5. Blockade of Th1 and Th2 Allows
Differentiation of IL-17-Producing T Cells
Dot plots show intracellular staining for IFN-g
or YFP expression and IL-17 of sorted naive
CD4+ T cells after 4 days of culture. Yeti
YFP2 naive CD4+ T cells cultured with DC
stimulated with LPS (A), and TGFb (B). Naive
CD4+ T cells cultured with DC stimulated
with LPS (C) or naive T cells stimulated in
the absence of DC with anti-CD3, anti-
CD28, IL-6/TNFa, and IL-1b (D), cultured in
the presence of anti-IL-4, anti-IL12/23 (p40),
and anti-IFNg. (E) The response of naive T
cells cultured in the presence of DC and
LPS with the antibodies shown in (C) and (D)
and, in addition, anti-TGFb. (F) Response of
naive T cells cultured in the absence of DC
(conditions as outlined in [D]) and including
the antbodies outlined for (E).T cells (data not shown), indicating sensitive crossregu-
lation of CD4 T cell subsets.
IL-17-Producing T Cells Do Not Express Th1 or Th2
Transcription Factors or Smad7
Restimulation of primary cultures containing IL-17-pro-
ducing T cells with IL-2 resulted in outgrowth of IFN-g
producers (Figure 6B). In contrast, the addition of IL-23
promoted further expansion of IL-17-producing T cells
(Figure 6C). This confirms the reported role of IL-23 in
supporting growth and survival of activated IL-17 pro-
ducers (Aggarwal et al., 2003; Langrish et al., 2005).
Finally, analysis of the expression of transcription fac-
tors showed clearly that IL-17-producing T cells express
neither GATA-3 nor T-bet or its target Hlx (Figures 6D–
6F), which further sets them apart as a distinct subset.
TFGb signaling is subject to negative regulation via
transcriptional induction of Smad7, which competes
for receptor-regulated phosphorylation of Smad2 andSmad3 by the activated TGFb receptor complex (Nakao
et al., 1997) and enhances receptor degradation (Shi and
Massague, 2003). As shown in Figure 6G, the inhibitor of
TGFb signaling, Smad 7 is induced in Th1 T cells but ab-
sent in Th2 and IL-17-producing T cells.
Discussion
This paper describes the in vitro differentiation of IL-
17-producing CD4+ T cells from naive CD4+ T cell pre-
cursors and provides evidence for the involvement of
a uniquely balanced combination of pro- and antiinflam-
matory cytokines. Dendritic cells stimulated via different
Toll-like receptors provide a range of proinflammatory
cytokines that promote the development of Th1 T cells,
notably IL-12 and IL-18. However, a similar stimulus in
the presence of TGFb1, a pleiotropic cytokine that is
made by multiple cells types (Gorelik and Flavell,
2002), deviates differentiation to IL-17-producing T
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185Figure 6. IL-17-Producing CD4+ T Cells Are Distinct from Th1 and Th2 Subsets and Are Maintained by IL-23
Dot plots show intracellular staining for IFN-g and IL-17 of sorted naive CD4+ T cells after 4 days of culture. Naive CD4+ T cells were activated with
plate bound anti-CD3 and anti-CD28 for 3 days in the presence of TGFb, IL-6, IL-1b, and TNFa and rested for 3 days (A), then restimulated with
plate bound anti-CD3 and anti-CD28 for 3 days in medium supplemented with IL-2 (B) or IL-23 (C) and rested for 4 days before analysis. mRNA
levels of the transcription factors T-bet (D), Hlx (E), and GATA-3 (F), and Smad inhibitor Smad7 (G) were determined in CD4+ T cells stimulated
with plate bound anti-CD3 and anti-CD28 for 3 days under neutral, Th1 (IL-12), Th2 (IL-4), or Th IL-17 (cytokine mix) polarizing conditions and
rested for 3 days before RNA isolation.cells. TGFb1 has a critical function as an antagonist of
Th1 development affecting IFN-g as well as T-bet (Gor-
elik et al., 2002; Lin et al., 2005), but also interferes
with Th2 differentiation (Chen et al., 2003a; Gorelik
et al., 2000; Heath et al., 2000). Indeed, a combination
of anti-IL-12/23, anti-IFN-g, and anti-IL-4 was recently
shown to support the development of IL-17-producing
T cells (Harrington et al., 2005; Park et al., 2005). Our
study confirmed that this combination of antibodies in
the presence of LPS-stimulated DC allows generation
of IL-17-producing T cells, and it should be noted that
we detected IL-17 differentiation in the absence of
IL-23. This is in agreement with a role of TGFb1 in block-
ing Th1 and Th2 differentiation, thus allowing the diver-
sion to IL-17 T cell differentiation.
However, our data indicate that there may be an addi-
tional, more active role for TGFb1 in this process, since,
even in the presence of antibodies that strongly inhibit
Th1 and Th2 generation, TGFb was essential to allow
IL-17 differentiation. Antibodies to TGFb abrogated the
positive effect of antibodies to IL-12/23, IFNg, and IL-4
on differentiation of IL-17-producing T cells, implicating
DC as the cellular source of TGFb1 in these cultures.
However, it appears that the amount of TGFb1 they pro-
duce in primary cultures is obviously not sufficient to
promote IL-17 differentiation without further blockade
of Th1/Th2-promoting cytokines. A critical balance
between IFNg- and TGFb-mediated signals crucially in-
fluences the extent of Smad3 activation (Ulloa et al.,1999), so that any interference with the IL-12/IFNg axis
will shift the balance in favor of TGFb.
Since disruption of TGFb1 signaling in T cells results in
inflammation and autoimmunity (Gorelik and Flavell,
2000; Kulkarni et al., 1993; Shull et al., 1992), it may at
first appear counterintuitive to invoke TGFb1 in the initi-
ation of a highly proinflammatory T cell subset. How-
ever, it has long been recognized that TGFb1 not only
has antiinflammatory potential but can, under certain
circumstances, also potentiate inflammation (Wahl,
1994). This dichotomy of action depends on local versus
systemic expression (Allen et al., 1990; Wahl et al., 1993),
as well as concentration and timing between TCR-trig-
gered activation and signaling through the TGFb recep-
tor (McKarns and Kaminski, 2000). Notably, local admin-
istration of TGFb1 precipitated inflammatory responses
and recruitment of neutrophils in experimental arthritis
models (Allen et al., 1990; Fava et al., 1991). These
experimental models predate the discovery of IL-17-
producing T cells, but since they evoke typical charac-
teristics of this proinflammatory T cell subset, it would
in fact be very interesting to reevaluate these models
in light of our findings concerning the role of TGFb1 in
the differentiation of IL-17-producing T cells.
In agreement with a recent publication (Harrington
et al., 2005), we did not find the Th1 lineage transcription
factor T-bet and its target, the homeoprotein Hlx (Mullen
et al., 2002), expressed in IL-17-producing T cells. How-
ever, T-bet-deficient mice are protected from EAE
Immunity
186(Bettelli et al., 2004; Lovett-Racke et al., 2004), although
this autoimmune disease appears to be mostly driven by
IL-17-producing T cells (Cua et al., 2003). While this may
indicate involvement of Th1 T cells in EAE, it is also
worth considering that Tbet expression in dendritic cells
is important for their function in innate immunity (Lugo-
Villarino et al., 2005) and thus may play a role in the dif-
ferentiation of IL-17-producing T cells. The absence of
Smad 7, an inhibitor of TGFb signaling (Hayashi et al.,
1997; Nakao et al., 1997), also sets IL-17-producing T
cells apart from Th1 T cells.
IL-6, the other obligatory component in the differenti-
ation of IL-17-producing T cells, has an important role in
many aspects of immune responses (Taga and Kishi-
moto, 1997). Notably, its absence results in decreased
induction of EAE as well as collagen-induced arthritis
(Alonzi et al., 1998; Eugster et al., 1998; Ohshima et al.,
1998; Okuda et al., 1998; Rochman et al., 2005), both dis-
eases in which IL-17 is strongly involved. Despite the
fact that TGFb1 and IL-6 alone were capable to drive
the initial differentiation of IL-17-producing T cells, their
numbers were amplified by IL-1b and TNF-a. Synergistic
roles of IL-6, TNF-a, and IL-1b have been described pre-
viously, and deficiency in any one component reduces
onset of severity of pathology (Hata et al., 2004). Since
IL-17 itself has been implicated in induction of TNF-a,
IL-1b, and IL-6 (Fossiez et al., 1998; Langrish et al.,
2005), it is likely that there is positive feedback control
also involving cytokine production from T cells once
IL-17-producing cells have been generated. However,
in the case of TNF-a, it seems clear that it is DC-derived,
not T cell-derived, TNF-a that is instrumental in driving
IL-17 differentiation, since IL-17 production in recipients
of adoptively transferred T cells from TNF-a-deficient
mice was found to be normal (Nakae et al., 2002).
IL-23, which has been implicated in the generation of
IL-17 responses from preactivated CD4+ T cells, does
not appear to play a role in de novo generation of IL-
17-producing T cells. The protection against induction
of EAE and CIA in p19 knockout mice, together with
the absence of IL-17-producing T cells in such mice,
was thought to reflect a direct involvement of IL-23 in
the generation of IL-17-producing T cells (Langrish
et al., 2005; Murphy et al., 2003). While p192/2 mice
were reported to have elevated levels of TNFa, IL-6,
and IL-1b early after immunization with MOG (Cua
et al., 2003), the levels of these cytokines were reduced
in p192/2mice 42 days after immunization with collagen,
when control mice showed chronic disease (Murphy
et al., 2003). Our data suggest that p192/2 mice are
capable of generating IL-17-producing T cells, but the
absence of IL-23 may compromise their survival and
thereby limit the positive feedback loop that upregulates
IL-6, IL-1b, and TNF-a. The importance of IL-23 in driving
the survival and expansion of activated IL-17 producers
as previously suggested (Aggarwal et al., 2003; Harring-
ton et al., 2005; Langrish et al., 2005; Park et al., 2005)
was confirmed in our study.
Although it is clear that there are many cellular
sources for TGFb1 (Fahlen et al., 2005; Letterio, 2005),
an intriguing feature in the generation of IL-17-produc-
ing T cells was the apparent involvement of Treg in the
differentiation of IL-17-producing T cells in our study.
What could be the contribution of Treg to this phenom-enon? Treg have been shown to secrete TGFb1 (Belghith
et al., 2003), and some of them express TGFb1 on their
surface (Nakamura et al., 2001), but the role of TGFb1
in their suppressive function is somewhat controversial
(Piccirillo et al., 2002). Given that DCs appear to be
able to secrete some TGFb themselves, an alternative
explanation for the function of Treg may be their strong
suppression of both Th1 and Th2 responses via the inhi-
bition of IFNg and IL-4. In addition, Treg may increase
the production of TGFb1 by DC. Furthermore, we have
recently shown that Treg induce MyD88-independent
IL-10 production in DC (M.V. and B.S., unpublished
data), whose suppression of IL-12 might aid the devel-
opment of IL-17-producing T cells. While anti-IL-10
was not sufficient to suppress IL-17 differentiation, it
nevertheless caused a reduction in the proportion of T
cells that were able to produce IL-17 (Figure 2C).
The perceived role of Treg is in downregulation of
inflammatory responses, whereas IL-17 is thought to be
highly proinflammatory. Under physiological conditions
in vivo, the number of Treg present in the vicinity of an on-
going infection may not be sufficient to skew T cell differ-
entiation. Furthermore, there may be a strict temporal reg-
ulation of the effect, since delaying the addition of Treg to
naive T cells for 6 hr abrogated the generation of IL-
17-producing T cells (data not shown). Nevertheless, the
potential connection of Treg that play a well-documented
protective role in inflammatory bowel disease (Powrie,
1995) and IL-17, which is beneficial at mucosal sites, rep-
resents another intriguing aspect of immune regulation.
Taken together, our data suggest an important role for
TGFb, which together with IL-6 can mediate the de novo
differentiation of IL-17-producing T cells from naive pre-
cursors. While part of the effect of TGFb1 consists of
suppressing Th1 and Th2 differentiation, thus allowing
diversion to IL-17 differentiation, the fact that blocking
of TGFb in the context of Th1/Th2 antibody blockade
abolishes IL-17 production suggests that it also has
a more direct role in the differentiation of IL-17-produc-
ing T cells. Our data furthermore provide a logical expla-
nation for the apparent paradox that TGFb can play both
anti- and proinflammatory roles in the immune system.
Experimental Procedures
Mice
C57BL/6, C57BL/6 Ly5.1, C57BL/6 Yeti (Stetson et al., 2003), C57BL/
6 MyD882/2, and C57BL/6 Rag12/2 mice were bred under SPF con-
ditions, and experimental animals were kept in conventional but
pathogen-free animal facilities at the National Institute for Medical
Research (London, United Kingdom) in accordance with local guide-
lines.
Cell Purification
Single-cell suspensions from spleens and lymph nodes were stained
with anti-CD25-phycoerthrin (PE) followed by anti-PE magnetic
microbeads (Miltenyi Biotec, Surrey, United Kingdom) and enriched
by positive selection on an AutoMACS (MACS, Miltenyi Biotec,
GmbH), according to the manufacturer’s instructions. The positive
fraction was then sorted on a Moflo cytometer (Cytomation, Fort
Collins, Colorado) to obtain pure populations of CD4+CD25+ T cells
(>99% purity); the negative fraction was sorted into CD252 CD44lo
CD62Lhi CD4+ T cells (>99.5% purity).
Generation of Bone-Marrow-Derived DC
Bone-marrow-derived DCs (BMDC) were generated as described
previously (Stockinger and Hausmann, 1994). Briefly, femurs and
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187tibia were flushed with culture medium, and 3 3 106 bone marrow
cells were cultured in petri dishes (NUNC) in 10 ml culture medium
containing 10% supernatant of Ag8653 myeloma cells transfected
with murine granulocyte macrophage colony stimulating factor
(GM-CSF) cDNA. On day 4 of culture, nonadherent granulocytes
were removed and GM-CSF medium replaced. Loosely adherent
cells were transferred to a fresh dish on day 6 of culture and used
from day 6 to day 8 as the source of dentritic cells (>95% purity).
In Vitro Stimulation and Exogenous Cytokines
The culture medium used was Iscove’s modified Dulbecco medium
(IMDM) (Sigma) supplemented with 5% heat-inactivated FACS, 2 3
1023 M L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin,
and 5 3 1023 M mercaptoethanol (all Sigma).
Cells were cultured in 2 ml volume, containing 1 3 105 BMDC,
2.5 3 105 sorted naive CD4+ T cells with or without 2.5 3 105
CD4+CD25+ T cells, stimulated with soluble 0.5 mg/ml anti-CD3
(45-2C11), or immobilized anti-CD3 (1 mg/ml) and 10 mg/ml anti-
CD28 (37.51) or 5 ml anti-CD3 and anti-CD28-coated beads (Dynal
Biotech, Oslo, Norway). TLR stimuli used were 100 ng/ml LPS
(from Salmonella Minnesota R595, ultrapure TLR4 grade) (Alexis
Biochemicals, Lausen, Switzerland), 200 nM CpG (1668) (Invitrogen),
100 mg/ml PolyI:C (Amersham Biosciences, New Jersey). Exogenous
cytokines used were TGFb (1 ng/ml) (Sigma), IL-1b (10 ng/ml), IL-4
(10 ng/ml), IL-6 (20 ng/ml), TNFa (10 ng/ml), (All ImmunoTools,
Germany), IL-12 (5 ng/ml) (Preprotech EC Ltd, United Kingdom),
and IL-23 (10 ng/ml) (kind gift from Dr. A. O’Garra).
Quantitative mRNA Analysis of Cytokines
and Transcription Factors
RNA was extracted using 1-bromo-3-chloro-propane (Sigma) and
reverse transcribed with oligo d(T)16 (Applied Biosystems, Branch-
burg, New Jersey) according to the manufacturer’s protocol. The
cDNA served as template for the amplification of genes of interest
and the housekeeping gene (Hprt) by real-time PCR, using TaqMan
Gene Expression Assays (Hprt, Mm00446968_m1; IL-2,
Mm00434256_m1; Tbet, Mm00450960_m1; GATA3, Mm00484683_m;
Hlx, Mm00468656_m1; Smad7, Mm00484741_m1) (all Applied Bio-
systems, Foster City, California), universal PCR Master Mix (Applied
Biosystems, Warrington, United Kingdom) and the ABI-PRISM 7900
Sequence Detection System (Applied Biosystems, Foster City, Cal-
ifornia). Target gene expression was calculated using the compara-
tive method for relative quantitation upon normalization to Hprt gene
expression.
Antibodies and Flow Cytometry
Anti-CD4 APC (RM4-5), anti-CD25 PE (PC61), anti-CD44 PE (IM7),
anti-CD62L APC (MEL14), anti-CD45.2 Biotin (104), anti-IFNg FITC
(XMG1.2), and anti-IL-6 (MP5-20F3) were purchased from eBio-
science (San Diego, California); Streptavidin APC was purchased
from Molecular Probes (Eugene, Oregon); and anti-IL-17 PE from
BD Biosciences (United Kingdom). Anti-TGFb (1D11.16) and isotype
control (Ox-1) were a kind gift from Dr. A. Cooke. Anti-CD3 (145-
2C11), anti-CD28 (37.51) anti-IFNg (R46A2), anti-IL-4 (11B11) anti-
IL-12/IL-23 p40 (C17.8), and anti-IL-10 (JES5 16E3) were purified
from hybridoma supernatant in our laboratory using standard proce-
dures. All antibodies were used at 10 mg/ml for blocking. For deter-
mination of intracellular cytokine production, cells were restimulated
with 500 ng/ml PdBu, 500 ng/ml ionomycin, and 1 mg/ml BrefeldinA
(all Sigma) for 4 hr at 37ºC. Cells were then stained for surface
markers, fixed in 1% paraformaldehyde in PBS, and permeabilized
with 0.1% NP40 PBS, followed by labeling with specific cytokine
Abs or isotype controls. Cells were analyzed on a FACSCalibur (Bec-
ton Dickinson, San Jose, California) using Cellquest software (Bec-
ton Dickinson) and further analyzed using FlowJo software (Tree
Star, Inc).
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